A detailed history of Ubs Asset Management Americas Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 331,260 shares of CABA stock, worth $758,585. This represents 0.0% of its overall portfolio holdings.

Number of Shares
331,260
Previous 403,136 17.83%
Holding current value
$758,585
Previous $3.02 Million 48.16%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.94 - $8.24 $283,191 - $592,258
-71,876 Reduced 17.83%
331,260 $1.56 Million
Q2 2024

Aug 13, 2024

BUY
$7.22 - $18.82 $2.82 Million - $7.34 Million
390,215 Added 3020.01%
403,136 $3.02 Million
Q1 2024

May 15, 2024

BUY
$16.79 - $25.38 $28,878 - $43,653
1,720 Added 15.36%
12,921 $220,000
Q4 2023

Feb 14, 2024

BUY
$12.21 - $23.36 $136,764 - $261,655
11,201 New
11,201 $254,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $66.4M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.